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Abstract
Objective: The factors associated with the development of immune reconstitution inflammatory syndrome in HIV patients
commencing antiretroviral therapy have not been fully elucidated. Using a longitudinal study design, this study addressed
whether alteration in the levels of T regulatory cells contributed to the development of IRIS in a West African cohort of HIV-1
and HIV-2 patients. Seventy-one HIV infected patients were prospectively recruited to the study and followed up for six
months. The patients were categorized as IRIS or non-IRIS cases following published clinical guidelines. The levels of
T regulatory cells were measured using flow cytometry at baseline and all follow-up visits. Baseline cytokine levels of IL-2, IL-
6, IFN-c, TNF-a, MIP-1b, IL-1, IL-12, IL-13, and IL-10 were measured in all patients.
Results: Twenty eight percent of patients (20/71) developed IRIS and were predominantly infected with HIV-1. Patients
developing IRIS had lower nadir CD4 T cells at baseline (p=0.03) and greater CD4 T cell reconstitution (p=0.01) at six
months post-ART. However, the development of IRIS was not influenced by the levels of T regulatory cells. Similarly,
baseline cytokine levels did not predict the onset of IRIS.
Conclusion: The development of IRIS was not associated with differences in levels of T regulatory cells or baseline pro-
inflammatory cytokines.
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Introduction
Immune reconstitution inflammatory syndrome (IRIS) results
from an exuberant immune response against residual antigens
(paradoxical IRIS) or viable pathogens (unmasking IRIS) in HIV
infected patients commencing antiretroviral therapy [1–3]. While
most IRIS develops in response to mycobacteria, a number of
other pathogens have also been associated with the development of
IRIS [4]. IRIS due to all causes develops in 3% to 39% of patients
who start ART, and TB-IRIS in 3% to 43% [5]. In two
prospective South African cohorts, all-cause IRIS developed in
10% of patients starting ART, and TB-IRIS developed in 23% of
patients who had started TB therapy prior to ART [6,7]. The peak
incidence of IRIS occurs 2 to 8 weeks after ART initiation, and
both paradoxical and unmasking IRIS are more common in
patients with a lower nadir CD4 prior to starting ART [8,9].
While IRIS often has a benign course, it can cause considerable
morbidity and occasionally be fatal [10].
The etiology of IRIS remains enigmatic, including its immu-
nological mechanism and predictors. Increased proliferation and
production of IFN-c from highly activated CD4 T cells towards
tuberculin, and increased levels of KIR- cd
+ T cells were observed
in TB- IRIS compared to non-IRIS ART controls [11,12]. A more
recent study demonstrated that IRIS patients displayed higher
levels of HLA-DR
+, Ki-67
+, PD-1
+ and effector memory subsets of
CD4 T cells compared to non-IRIS controls [13]. Similarly, using
a model of Mycobacterium avium (M. avium) challenge in
lymphopenic mice, Barber et al., demonstrated the onset of
symptoms consistent with IRIS after injection of exogenous CD4
T cells [14]. Similarly, the levels of activated CD8 T cells are
elevated in IRIS patients compared to ART controls, suggesting
that these cells may also contribute to the development of IRIS
[2,15].
T regulatory cells (Tregs) are committed suppressors of the
immune system. While multiple subtypes have been described, the
best characterized remain the natural Tregs, which originate in
the thymus yet can also be induced in the periphery. Besides CD4
and CD3, these cells are defined by the constitutive expression of
the transcription factor Forkhead Box protein 3 (FOXP3) [16–17].
Tregs function by suppressing the secretion of cytokines and
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response to microbial and self-antigens [20–21]. Previous studies
analyzing the role of Tregs in IRIS conducted using a cross-
sectional study design did not show any differences in their levels
between IRIS and non-IRIS cases [22–23]. However, Seddiki
et al., reported that the suppressive ability of Tregs in M.avium
IRIS cases was lower than that observed in non-IRIS cases [23].
The clinical resemblance of IRIS to paradoxical reactions, or
a hyperactive immune system, suggests that the balance between
immune activation and regulation is disturbed early on during
ART. Using a prospective longitudinal study design we focused on
the dynamics of Tregs following ART initiation and tested the
hypothesis that (all-cause) IRIS results from a relative delay in the
reconstitution of FOXP3 positive T regulatory cells. In addition,
we assessed whether baseline plasma cytokines could predict the
occurrence of IRIS after initiation of ART. The results from this
study argue against a significant role for Treg levels, either
proportions or absolute numbers, as predictors of the development
of IRIS.
Results
Incidence of IRIS in the Study Cohort
Of 80 patients enrolled after informed consent, 71 (89%)
completed more than 12 weeks of ART without an interruption of
greater than one week. One patient was found to have CD4 count
.800 cells/ml twice on repeat baseline testing, and was sub-
sequently taken off ART. Four patients were lost to follow-up
before 12 weeks, and 2 patients interrupted ART for 1 month.
Three patients died, of whom two had interrupted ART for more
than four weeks prior to death without IRIS symptoms recorded at
the last visit. One patient, in whom IRIS could not be excluded,
died after 8 weeks on ART.
Of the 71 patients included in the analysis, 21 (30%) developed
symptoms consistent with IRIS using the criteria set out by
Haddow et al [7] (Figure1).
IRIS patients typically had highly advanced disease and
commenced therapy with a significantly lower nadir CD4 count
than non-IRIS patients (60 versus 120 cells/ml, p=0.03, Figure 2).
However, the IRIS group also showed a significantly greater
increase in absolute CD4 T cells levels compared with non-IRIS
group six months after commencement of antiretroviral therapy
(150 versus 100 cells/ml, p=0.04). All subjects showed excellent
responses to treatment and 92% of patients had undetectable viral
loads at the end of the follow-up period (Table 1). The majority of
patients that developed IRIS showed symptoms within the first
month after initiation of ART (16 of 20 (80%)). The median
duration of IRIS symptoms was 49 (28–91) days. Pathogens were
rarely identified, while the lung and skin/mucosal surfaces were
involved in most cases (Table 2). The combination of fever and
cough with or without other symptoms was present in half of the
cases, and 5 of these 8 patients were among the 6 that had a history
of completing TB treatment prior to starting ART.
T Regulatory Cell Reconstitution in Patients with and
without IRIS
Tregs were defined as CD4 T cells co-expressing the
transcription factor FOXP3. The gating strategy employed to
enumerate Tregs as a percentage of total CD4 T cells is shown in
Figure 3. An alternative definition that included CD25
+ as part of
the definition of Tregs was also used for comparison (Figure 4).
The percent Treg levels expressed as CD4
+CD4
+FOXP3
+ were
similar between the IRIS (13.31%, 95% CI: 9.1–19.2) and non-
IRIS group (15.6%, 95% CI: 11.3–18.9) at baseline, while the
absolute levels of Tregs were lower in the IRIS group (6.3 cells/l,
95%CI: 2.4–16.2) versus the non-IRIS group (14.8 cells/ul,
95%CI: 5.2–28.5), although this lost significance after adjusting for
total CD4 levels (p =0.08, data not shown).
The median percentage of Tregs declined after initiation of
ART in the non-IRIS group but remained high in the IRIS group
until three months post ART initiation. At six months post ART
initiation, the percentage of Tregs had declined to significantly
lower levels than at baseline in both the IRIS and non-IRIS
Figure 1. Classification of patients recruited to the study according to IRIS status.
doi:10.1371/journal.pone.0039213.g001
IRIS and Tregs in West African HIV Cohort
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used to analyze whether the magnitude or trend of Tregs differed
between the IRIS and non-IRIS groups during the six-month
study period. The trend of Tregs was not significantly different
between the two groups and this was irrespective of whether Tregs
were defined as CD3
+CD4
+FOXP3
+ (p=0.1452) or
CD3
+CD4
+CD25
+FOXP3
+ (p =0.2815) (Figure 4A and 4B).
Baseline Cytokines and Chemokines do not Predict IRIS
Plasma cytokine levels were measured at baseline to determine
whether these could be used to predict the onset of IRIS. The
levels of IL-12, IL-13, and IL-17 were below the limit of the assay
in all patients tested. Plasma levels of IL-2, IL-6, IFN-c MIP-1b,
IL-10 and TNF-a were comparable in all groups (Table 3). There
was no significant correlation observed between the levels of
CD4
+FOXP3
+ cells and any of the cytokines measured.
Discussion
IRIS remains elusive, both as a clinical phenotype with
imprecise case definition, and as an immunological phenomenon
during the massive overhaul of the immune system as people start
ART. Several case definitions have been proposed for IRIS, both
TB-IRIS [24] and all-cause IRIS [7]. We applied the most recent
all-cause IRIS case definition used in many other studies [7].
The incidence of IRIS (28%) in our study was comparable with
a similar study in South Africa, Mozambique and lower than
reported in Senegal [5,25]. IRIS patients had significantly lower
nadir CD4 T cell counts and showed a greater recovery of CD4
T cell counts compared with the non-IRIS group. These results
re-affirm that a low CD4 T cell count at the time of initiating ART
is a risk factor for the development of IRIS [4,9,26,27].
The majority of IRIS cases developed within the first month
after starting on ART. In addition the IRIS patients showed
a higher recovery of CD4 T cells compared to the non-IRIS
group. These findings reiterate the need for commencing ART
early and for close monitoring of HIV infected patients who
initiate ART. Unique to this study, approximately 10% of subjects
included were infected with HIV-2. These individuals showed
similar dynamics in viral suppression and CD4 reconstitution to
HIV-1 patients, and two of these patients developed IRIS. This
emphasizes the point that in HIV-2 infected individuals who
progress to AIDS, the clinical course often mirrors that of HIV-1
infected individuals.
Deciphering the immunopathogenesis of IRIS remains a chal-
lenge. Higher levels of immune activation prior to commencement
of ART have been identified as a risk factor for development of
Figure 2. Comparison of CD4 and Viral load levels in IRIS and non-IRIS patients. A) CD4 levels (cells/ml) and B) Viral loads (copies/ml) after
initiation of ART in study subjects classified by IRIS status. The error bars represent the interquartile ranges.
doi:10.1371/journal.pone.0039213.g002
Table 1. Patient characteristics.
All IRIS Non-IRIS P value
N (%) 71 20 (28%) 51 (72%)
Male sex 25 (35%) 5 (24%) 20 (39%)
Age
(median)
41 39 43 ns
CD4 nadir
(median)
100
(30–160)
60
(20–130)
120
(45–180)
0.03
CD4 increase
in 6 mo
(median)
120
(70–205)
150
(120–330)
100
(50–180)
0.01
HIV type
1 58 (82%) 17 (85%) 41 (80%) ns
2 9 (13%) 2 (10%) 7 (14%) ns
dual 4 (6%) 1 (5%) 3 (6%) ns
VL ,100
copies/ml
65 (92%) 18 (90%) 47 (92%)
Ethnicity
Mandinka 28 (39%) 7 (30%) 21 (41%) ns
Wolof 9 (13%) 2 (10%) 7 (14%) ns
Fula 8 (11%) 3 (10%) 5 (10%) ns
Jola 8 (11%) 3 (10%) 5 (10%) ns
Other 18 (25%) 5 (20%) 13 (25%) ns
ART 24 wk 61 (86%) 19 (95%) 42 (69%) ns
IRIS=Immune reconstitution inflammatory syndrome.
ADE=Adverse drug effects.
VL=Viral load, ,100=undetectable within first 9 months of ART.
ART=Antiretroviral therapy.
ART 24 wk=No interruption in ART use .3 days over 24 weeks.
ns=not significantly different, p.0.05.
doi:10.1371/journal.pone.0039213.t001
IRIS and Tregs in West African HIV Cohort
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39213Figure 3. Gating strategy employed to determine the percentage of CD3
+CD4
+FOXP3
+ and CD3
+CD4
+CD25
+FOXP3
+ cells. A) Forward
Scatter vs Side Scatter B) CD3 versus CD4 within the lymphocyte gate C) FOXP3 versus CD4 within the CD4
+CD3
+ gate D) FOXP3
+ versus CD25
+ within
the CD3
+CD4
+ gate.
doi:10.1371/journal.pone.0039213.g003
Figure 4. Change in T regulatory cells in IRIS and non-IRIS patients after the initiation of antiretroviral therapy. A) Percentage of total
CD3
+CD4
+FOXP3
+ T cells or B) CD3
+CD4
+CD25
+FOXP3
+ after initiation of ART till six months post ART. The trend lines denote the median percent
values for each group over the 6-month study period.
doi:10.1371/journal.pone.0039213.g004
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39213IRIS [11–12]. Hence, we hypothesized that Treg dynamics in
patients commencing ART could distinguish IRIS versus non-
IRIS cases. Although we noted lower levels of absolute Tregs at
baseline in those patients who later developed IRIS, percentage
levels of Tregs were similar in both groups of patients. The
proportion of Tregs in all patients declined steeply after the
initiation of ART in all patients, which is consistent with the results
of a recently published study [28]. However there appeared to be
a slower decline in Treg levels in the IRIS group, and persistently
higher Tregs after the occurrence of IRIS could be a compensatory
mechanism for the inflammatory syndrome. Due to the high
variability these were not significantly different from the non-IRIS
group. However, we cannot exclude the possibility that Treg
dynamics may differ within the first month (wherein the majority
of IRIS cases develop) after initiation of ART between IRIS and
non-IRIS cases.
Our results are consistent with a previous study comparing Treg
levels in TB patients commencing ART, which similarly showed
no significant differences in the percentage of Tregs in TB-IRIS at
the time of IRIS presentation versus non-IRIS cases two weeks
post ART treatment [22]. Neither the TB-IRIS study nor our own
included functional assays. A cross-sectional study on 8 patients
with Mycobacterium avium-related IRIS identified high numbers
of Tregs which were unable to suppress the secretion of pro-
inflammatory cytokines IFN-c, TNF-a and IL-6 in vitro [23]. It is
therefore feasible that despite high frequencies of Tregs, IRIS may
result from inadequate suppressive function of these cells. Further
studies that quantitate Treg function at ART initiation and prior
to development of IRIS can clarify whether Treg dysfunction
rather than frequencies indeed contributes to IRIS.
It appears that the mechanism of IRIS in patients commencing
anti-retroviral therapy, including the role of T-cells, differs by
pathogen [29–30]. Treg levels specifically were not significantly
different between TB-IRIS cases and non-IRIS cases in two
studies [22–23], while Tregs were elevated in cryptococcal
meningitis-IRIS cases [31]. Since we were unable to determine
the pathogen responsible for development of IRIS in most of our
patients, we can only speculate that the lack of association between
Treg levels and IRIS may be a result of heterogeneity in the
causative pathogens in the IRIS patients.
Higher levels of pro-inflammatory cytokines before resumption
of ART have been linked to a greater risk of developing IRIS [32–
33]. Even though there were higher median levels of IL-6 and
IFN-c in the IRIS group compared to the non-IRIS group at
baseline, these differences were small and did not predict the
development of IRIS.
In summary the results of this study show that neither Treg
levels nor cytokine levels predict the onset of all-cause IRIS.
Further investigation is required to assess Treg function, in order
to determine whether qualitative rather than quantitative Treg
differences play a role in the development of IRIS.
Methods
Clinical
In a prospective observational cohort conducted at the MRC
Laboratories in The Gambia, consecutive ART naı ¨ve adult
African patients with a CD4 count below 200, scheduled to
commence ART, were recruited after giving informed consent.
We included people infected with HIV-1, HIV-2, or dual
infection. Patients were screened for TB at baseline with symptom
review and chest radiographs. They were encouraged to return to
the clinic anytime they developed new symptoms. On their
scheduled return visits at 2, 4, 8, 12, and 24 weeks post ART
initiation, patients were asked IRIS specific questions prior to
seeing a physician, including whether they had a fever, night
sweats, cough, headache, nausea, abdominal pain, weakness,
visual problems, skin lesions, or any swelling. The treating
physicians assessed each patients’ likelihood of having IRIS, and
all cases were subsequently reviewed and classified as IRIS based
on the criteria outlined by Haddow et al [7].
Laboratory
Patients had viral load, full blood count and lymphocyte subsets
determined as part of their routine medical care at baseline, 12
and 24 weeks. In addition, patients donated blood for flow
cytometry analysis at baseline and the routine follow-up visits at 4,
8, 12 and 24 week visits. Plasma was stored at 220uC.
Enumeration of Tregs using Whole Blood FACS Staining
Fresh whole blood (150 ml) was stained within 6 hours using
conjugated monoclonal antibodies to CD25-FITC, CD4-PerCP,
CD3-PE (Becton Dickinson, USA) and FOXP3-APC (Clone:
PCH101, Ebiosciences, USA) using the recommended intracellu-
lar staining protocol for FOXP3. Single stains for CD8 were used
to adjust compensations before acquisition of samples on a 4-
colour FACS Calibur. A minimum of 150,000 events were
collected in the PBMC gate. The data were analyzed for percent of
CD3+CD4+ as well as CD3+CD4+CD25+ T cells expressing
FOXP3, using the FlowJo software.
CD4 T cell counts. Enumeration of CD4 levels (CD4% of
total CD3 T cells) was done using BD MultiTest reagents and
MultiSet software (BD Biosciences, USA) as recommended by the
manufacturers.
Viral load measurements. HIV-1 and HIV-2 plasma viral
loads were quantified using a PCR based method [34–35] using
Table 3. Comparison of cytokine levels between IRIS and non-IRIS patients before commencing ART. The interquartile ranges are
displayed in brackets beside median values for each group and cytokine measured.
Analyte (pg/ml)
IRIS category IL-2 IL-6 IFN-c MIP-1b TNF-a IL-10
Non-IRIS 0.765 7.4 10.65 73.65 0 2.84
(0–12.27) (3.16–10.83) (4.57–34.66) (54.11–124.91) (0–1.67) (1.21–4.22)
IRIS 4.86 11.16 27.11 72.52 2.1 4.38
(0–28.74) (3.84–25.47) (4.57–243.78) (56.49–98.21) (0–4.17) (1.45–9.98)
p value 0.275 0.45 0.09 0.34 0.845 0.65
doi:10.1371/journal.pone.0039213.t003
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PCR products by enzyme-linked oligonucleotide binding. The
assay has a lower limit of detection of 100 RNA copies/ml.
Measurement of plasma cytokine levels. Plasma levels of
IL-2, IL-6, IL-10, IL-12, IL-13, IL-17, TNF-a, MIP-1b and IFN-c
were measured at baseline using a single Bioplex assay (Bio-Rad,
USA) on undiluted plasma using standards and controls as
recommended by the manufacturer.
Analysis
The final classification of the patients resulted in 2 categories of
IRIS and non-IRIS. Patients who interrupted ART .1 week, or
stopped ART before 12 weeks, were excluded from the
immunological analysis. Longitudinal percent levels of Tregs were
analyzed using generalized estimating equations (equal correlation
structure) adjusting for age, sex, ethnicity and viral loads. Cross-
sectional analysis of baseline Treg levels was compared between
the IRIS- and non-IRIS groups adjusted for the same possible
confounders as mentioned above using the non-parametric
Kruskal-Wallis test. Tests with a p-value ,0.05 were considered
statistically significant.
All analyses were performed in Stata (version 11) and figures
were drawn using Prism (version 5).
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